Objective. To evaluate the effect of golimumab on haemoglobin levels in patients with RA, PsA or AS.
Introduction
The prevalence of anaemia in patients with RA ranges from 30% to 60%, although a paucity of published data exists [1, 2] . In a recent epidemiological study of patients with RA, Wolfe et al. [2] reported that lower haemoglobin levels were associated with increased disease activity as measured by the number of tender and swollen joints, ESR, CRP level, HAQ score and assessments of pain and fatigue. Anaemia independently contributes to physical disability in patients with RA [3] .
Anaemia of chronic disease [4] , also referred to as anaemia of inflammation, may occur in patients with acute or chronic immune activation and is associated with the production of proinflammatory cytokines including IL-1-beta, IL-6 and TNF-a [4, 5] . This type of anaemia is a function of disordered homeostasis. Reticuloendothelial system cells retain greater than normal amounts of iron; thus, less iron is readily available for erythroid progenitors as well as erythropoiesis [4] . Hepcidin, a hormone known to reduce iron absorption from the gastrointestinal tract, is most directly linked with IL-6 [6]. Circulating hepcidin levels are elevated in patients with active RA and thus may contribute to the development of anaemia in these patients; TNF inhibitors, through their inhibitory effects on IL-6, may indirectly inhibit hepcidin and thereby reverse this effect [7] . Treatment for anaemia of inflammation is directed at treating the underlying cause of inflammation.
The pathophysiology of anaemia in RA remains to be fully elucidated; however, the cytokine TNF-a, along with other proteins, has been associated with the development of anaemia in RA patients by its role in the inhibition of erythropoiesis [6, 8, 9] . In patients with RA, improvements in haemoglobin levels occur after treatment with infliximab, a biologic TNF-a inhibitor [5, 10, 11] . Here, we evaluated the effect of golimumab, a TNF-a inhibitor that is administered s.c. every 4 weeks, on haemoglobin levels in patients from five large, phase 3, randomized, placebocontrolled studies of rheumatic diseases including RA, PsA and AS.
Materials and methods
Patient data were obtained from five multicentre, doubleblind, randomized, placebo-controlled studies of golimumab. The designs of each of these studies have been described in detail previously [1216] .
In GO-BEFORE [12] , patients with active RA who had not previously received MTX were randomly assigned to receive placebo plus MTX, golimumab 100 mg plus placebo, golimumab 50 mg plus MTX or golimumab 100 mg plus MTX.
In GO-FORWARD [13] , patients with active RA despite previous treatment with MTX were randomly assigned to receive placebo plus MTX, golimumab 100 mg plus placebo, golimumab 50 mg plus MTX or golimumab 100 mg plus MTX. Patients were required to be on a stable dose of MTX for 54 weeks prior to study drug administration. At week 16, all patients (except those in the 100 mg plus MTX group) who had <20% improvement in their tender and swollen joint counts entered early escape.
In GO-AFTER [14] , patients with active RA who had previously received 51 TNF-a inhibitor were randomly assigned to receive placebo, golimumab 50 mg or golimumab 100 mg. At week 16, all patients (except those in the 100-mg group) who had <20% improvement in their tender and swollen joint counts entered early escape.
In GO-REVEAL [15] , patients with active PsA were randomly assigned to receive placebo, golimumab 50 mg or golimumab 100 mg. At week 16, all patients (except those in the 100-mg group) with <10% improvement in their tender and swollen joint counts entered early escape.
In GO-RAISE [16] , patients with active AS were randomly assigned to receive placebo, golimumab 50 mg or golimumab 100 mg. At week 16, all patients (except those in the 100-mg group) who had <20% improvement in total back pain and morning stiffness entered early escape.
All golimumab injections were administered every 4 weeks. Patients in GO-BEFORE and GO-FORWARD also received concomitant MTX according to the protocol and their assigned treatment group. Patients in the other studies continued concomitant DMARDs, including MTX, SSZ or HCQ, at stable doses if they were receiving them at baseline. In GO-AFTER, GO-REVEAL and GO-RAISE, concomitant MTX/DMARD therapy was not required. All studies excluded patients with haemoglobin levels <8.5 g/dl, creatinine levels >1.5 mg/dl and uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric or cerebral disease.
Patients were defined as anaemic if their haemoglobin levels were below the age-and sex-specific normal range of the central laboratory (Quintiles Laboratories, Smyrna, GA, USA). Normal haemoglobin ranges for the central laboratory were 11.616.2 g/dl for women aged 65 years or younger, 11.016.1 g/dl for women aged 66 years or older, 13.017.5 g/dl for men aged 65 years or younger and 12.617.7 g/dl for men aged 66 years or older. Patients were excluded from the analysis if they received i.v. iron, recombinant human erythropoietin or a blood transfusion at any time through week 24. Patients in each study were allowed to continue stable doses of concomitant NSAIDs or corticosteroids (up to 10 mg/day prednisone equivalent) that they were receiving at study entry. None of the studies excluded NSAID or corticosteroid use.
We also categorized anaemia based on ferritin levels to separate patients whose low haemoglobin levels were the result of iron deficiency from those with anaemia of inflammation. Patients with anaemia and ferritin levels 560 ng/ml were considered to have anaemia of inflammation. Patients with anaemia and ferritin levels 515 and <60 ng/ml were also evaluated as a group that included patients with a mixture of iron deficiency and inflammatory anaemia (hereafter referred to as anaemia of mixed aetiology). This group excluded patients with very low iron levels (patients who had ferritin levels <15 ng/ml were considered to have pure iron deficiency anaemia).
Patients with pure iron deficiency anaemia were included in the analyses of patients with anaemia, but excluded from the analysis of patients with anaemia of mixed aetiology and anaemia of inflammation. Analyses of patients with anaemia and patients with anaemia of inflammation were prespecified in the original study protocols and statistical analysis plans; analyses of patients with anaemia of mixed aetiology were post hoc.
The DAS28 (using CRP) [1719] was used to assess disease activity in RA and PsA. The BASDAI [20] was used to assess disease activity in AS.
Statistical analysis
Changes from baseline in haemoglobin levels at week 14 (week 16 for GO-BEFORE) and at week 24 were analysed. For patients with missing haemoglobin values at week 14, the last non-missing haemoglobin value obtained prior to week 14 was used as the week-14 value. For patients who entered early escape at week 16, the week-24 haemoglobin value was replaced with the week-16 value, except in GO-BEFORE in which there was no early escape prior to week 24. Continuous variables were compared using analysis of variance on the van der Waerden normal scores. Medians and interquartile ranges were used to summarize the data because they were not normally distributed.
Results

Patient characteristics
A total of 2303 patients were included in this analysis. At baseline, approximately 21% of patients in the RA studies (320/1542), 9% of patients in the PsA study (37/405) and 15% of patients in the AS study (53/356) were anaemic ( Table 1) . The proportions of patients with anaemia were similar in the control and golimumab groups in the RA and AS studies but not in the PsA study, in which approximately 4% of patients in the placebo group and 11% of patients in the golimumab group were anaemic at baseline. Across all studies, 27% of anaemic patients had anaemia of inflammation, which represents 5% of the total study population.
Among all patients, median baseline haemoglobin levels were generally lower for patients in the golimumab group in the RA studies (12.8 g/dl) than for those in the PsA and AS studies (13.9 g/dl; Table 1 ). Also, the RA and PsA study cohorts tended to be older and the RA cohort was predominantly female (approximately 81%), whereas most patients in the PsA and AS studies were male (approximately 60% and 72%, respectively) ( Table 1) .
Baseline clinical characteristics for patients with anaemia were generally similar to those of the study population as a whole. However, patients with anaemia had higher median CRP levels than the overall population. Patients with anaemia of inflammation had the highest levels of CRP with the exception of those patients in the placebo group of the PsA study.
Change in haemoglobin levels from baseline Among anaemic patients from all five studies, the median [interquartile range (IQR)] change from baseline to week 14/16 in haemoglobin level was 0.3 g/dl (À0.30.8 g/dl) in the control group and 0.9 g/dl (0.21.6 g/dl) in the golimumab group (P < 0.001) (Fig. 1A ). Among patients with anaemia of mixed aetiology, the changes were 0.4 g/dl (À0.21.2 g/dl) in the control group and 0.7 g/dl (0.01.3 g/dl) in the golimumab-treated group (P = 0.305) (Fig. 1C ). Among patients with anaemia of inflammation, the changes were 0.2 g/dl (À0.40.8 g/dl) in the control group and 1.4 g/dl (0.72.1 g/dl) in the golimumab-treated group (P < 0.001) (Fig. 1E) . Changes from baseline to week 24 were similar to those at week 14 in all groups (Fig. 1B, D 
and F).
Among patients with anaemia in the combined RA studies, those who received golimumab had statistically significantly greater improvement in haemoglobin levels between baseline and week 14 than those who received control treatment. Differences between the treatment groups were also evident in the PsA study at week 14 ( Fig. 1A) . Similar results were seen among patients with anaemia of inflammation ( Fig. 1E and F ). Among patients with anaemia of mixed aetiology, no statistically significant differences were observed between treatment groups ( Fig. 1C and D ).
Inflammation and changes from baseline in haemoglobin levels
We used CRP to evaluate the relationship between changes in haemoglobin levels and inflammation. Among patients who received golimumab, changes in haemoglobin from baseline to week 14 were significantly greater in patients with elevated CRP levels at baseline (>0.6 mg/dl) compared with patients with normal CRP levels at baseline (40.6 mg/dl) ( Table 2) . Although the differences were not always statistically significant, improvement was consistently greater among patients with CRP >0.6 mg/dl at baseline (Table 2) . Among patients who received golimumab in all studies, there was a significant negative correlation between changes in haemoglobin and CRP from baseline to week 14 (À0.396, P < 0.001) and week 24 (À0.385, P < 0.001).
Disease activity and changes from baseline in haemoglobin levels Spearman correlation analyses were performed to assess the relationship between change from baseline in disease activity, as measured by DAS28 (using CRP) in RA and PsA and by BASDAI in AS, and change from baseline in haemoglobin levels at week 14 for the three anaemia populations (Table 3 ). In RA, the moderate statistically significant correlations were negative in direction and were observed consistently among patients in the golimumabtreated groups, but not among patients who received placebo. In the RA studies, the correlations were stronger for patients with anaemia of mixed aetiology and patients with anaemia of inflammation than for patients with www.rheumatology.oxfordjournals.org General pain was assessed in the RA and PsA studies using a VAS (010 cm). Only night pain was assessed in the AS study (VAS, 010 cm).
c Physical function was measured in the RA and PsA studies using the HAQ (range 03) and in the AS study using the BASFI (range 010). For patients with anaemia at baseline (A and B), patients with anaemia of mixed aetiology (ferritin 515 ng/ml and <60 ng/ml) at baseline (C and D) and patients with anaemia of inflammation (ferritin 560 ng/ml) at baseline (E and F). Data for patients who received golimumab or placebo are shown for all studies, the three RA studies combined and the PsA and AS studies separately. *P < 0.05, **P < 0.01, y P < 0.001 using an analysis of variance on the van der Waerden normal scores. anaemia. In the PsA and AS studies, sample size is small; thus there is insufficient information to draw a conclusion.
Discussion
Although the pathogenesis and incidence of anaemia may differ between RA, PsA and AS, studies have demonstrated that TNF inhibition is an effective treatment for all three diseases and may also improve comorbid conditions [21] . The current post hoc analysis demonstrates for the first time a significant impact of golimumab on haemoglobin levels in patients with anaemia who participated in one of five phase 3, randomized, placebo-controlled studies of golimumab in patients with RA, PsA or AS.
Because the number of patients with anaemia in each of the individual golimumab studies was small, we initially combined the data to evaluate the effect of golimumab on haemoglobin levels. The results indicate that anaemic patients who received golimumab had significantly greater improvement in haemoglobin levels than those who received placebo. Patients with anaemia of inflammation, in which anaemia is associated with sufficient iron levels (indicated by ferritin levels 560 ng/ml), showed greater improvement in Patients were observed from baseline to weeks 14/16 and 24 and were considered to be anaemic if their haemoglobin levels were less than the age-and sex-specific normal range of the central laboratory. b Patients were considered to have anaemia of mixed aetiology if their haemoglobin levels were below the normal range for the central laboratory and their ferritin levels were 515 ng/ml and <60 ng/ml. Patients were considered to have anaemia of inflammation if their haemoglobin levels were below the normal range for the central laboratory and their ferritin levels were 560 ng/ml. All P values are from analysis of variance on the van der Waerden scores comparing changes from baseline in haemoglobin levels in patients with normal CRP levels at baseline (40.6 mg/dl) vs those in patients with elevated CRP levels (>0.6 mg/dl).
haemoglobin levels than the population of anaemic patients as a whole. This is consistent with previously reported observations among anaemic RA patients treated with infliximab [11] .
For the combined cohort of all five studies (three RA, one AS and one PsA), the improvement in haemoglobin levels was similar to that in the individual cohorts from the three RA studies and the AS study. The improvement in haemoglobin levels in the AS population following treatment (between placebo-and golimumab-treated patients) was particularly marked, despite the small number of evaluable patients. In the PsA study, the number of anaemic patients was not evenly distributed between placebo-and golimumab-treated groups at baseline. Because there were so few anaemic patients in the placebo group, the results from the PsA study should be interpreted with caution.
Approximately 20% of patients in the RA studies had anaemia at baseline, while smaller proportions of patients in the PsA and AS studies had anaemia (9% and 15%, respectively) at baseline. Differences in age and sex were observed among the patients with the various forms of inflammatory arthritis, with older patients in the RA and PsA cohorts, a predominantly female population in the RA cohort and a predominantly male population in the PsA and AS cohorts. These differences in baseline characteristics may account, in part, for variances in mean haemoglobin levels between the groups at baseline and thus for the observed differences after golimumab treatment. The prevalence of anaemia in all three of these studies was lower than the prevalence of anaemia reported in earlier studies [11] . This is consistent with the trend towards decreased baseline RA disease activity over time observed in another study. The same trend was observed in an analysis of baseline characteristics among RA patients enrolled in randomized clinical trials of TNF-a inhibitors that were conducted between 1993 and 2008 [22] .
The subset of patients with anaemia had higher CRP levels at baseline than the overall study population. This result is consistent with epidemiological data from Wolfe and Michaud [2] , which indicate that the CRP level is the strongest predictor of anaemia in patients with RA. Our data indicate that the CRP level may also be a predictor of anaemia for patients with PsA or AS. Patients with elevated CRP levels at baseline who received golimumab exhibited greater improvements in haemoglobin levels at weeks 14 and 24 than those with normal CRP levels. The improvement in haemoglobin levels with treatment also correlated with an improvement in disease activity.
Identifying a specific cause of anaemia in patients with inflammatory diseases is difficult because haemoglobin levels can be affected by a variety of factors, including vitamin B12 deficiency, folic acid deficiency, NSAID-induced blood loss resulting from gastritis, iron deficiency from other causes and anaemia of inflammation [23] . In addition, the majority of RA patients are women, and anaemia is common among premenopausal women because they have menstrual bleeding. Thus, patients with inflammatory disease may have a mixture of iron deficiency anaemia and anaemia of inflammation.
The effect of inflammatory cytokines on ferritin levels confounds the diagnosis of anaemia of inflammation in the setting of active inflammatory disease [24] , as ferritin is an acute phase reactant. Recent evidence suggests that hepcidin may be a better marker of anaemia of inflammation [25] and could aid in differentiating this form of anaemia from iron deficiency anaemia in the setting of inflammation. We did not measure hepcidin in the clinical trials analysed in this study. Instead, we attempted to focus on anaemia of inflammation by excluding patients with low ferritin levels who presumably would have had a significant component of iron deficiency. Patients with anaemia caused by iron deficiency would not be expected to exhibit increased haemoglobin levels after anti-TNF-a therapy. However, iron deficiency potentially caused by NSAID-induced gastrointestinal blood loss cannot be excluded in these patient groups. Patients who experience a reduction in disease activity after treatment with a TNF-a inhibitor may decrease NSAID use [26] , which would lessen possible gastrointestinal blood loss.
This pooled analysis of data from five randomized, placebo-controlled studies of golimumab in patients with rheumatic diseases shows that golimumab improved haemoglobin levels in patients with anaemia, particularly in those patients with elevated CRP at baseline.
Rheumatology key messages
. Patients with RA, PsA and AS may have anaemia caused by inflammation, iron deficiency or both. . Golimumab improves haemoglobin levels, particularly among RA patients with anaemia of inflammation.
